| Content Provider |
World Health Organization (WHO)-Global Index Medicus |
| Author |
Li, Xiaosong Bowles, Nicole P. Li, Zhiying Karatsoreos, Ilia N. Makriyannis, Alexandros M. Hillard, Cecilia J. Kunos, George Vemuri, V. Kiran Hill, Matthew N. Schwartz, Gary J. Wood, Jodi-anne Tamashiro, Kellie L. K. Mcewen, Bruce S. |
| Description |
Author Affiliation: Bowles NP ( Laboratories of Neuroendocrinology and nbowles@mail.rockefeller.edu mcewen@mail.rockefeller.edu mnhill@ucalgary.ca.); Karatsoreos IN ( Laboratories of Neuroendocrinology and Department of Integrative Physiology and Neuroscience, Washington State University, Pullman, WA 99164); Li X ( Departments of Medicine and Neuroscience, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461); Vemuri VK ( Center for Drug Discovery, Department of Pharmaceutical Sciences and Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115); Wood JA ( Center for Drug Discovery, Department of Pharmaceutical Sciences and Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115); Li Z ( Molecular Genetics, The Rockefeller University, New York, NY 10065); Tamashiro KL ( Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205); Schwartz GJ ( Departments of Medicine and Neuroscience, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461); Makriyannis AM ( Center for Drug Discovery, Department of Pharmaceutical Sciences and Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115); Kunos G ( National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892); Hillard CJ ( Department of Pharmacology and Toxicology and Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, WI 53226); McEwen BS ( Laboratories of Neuroendocrinology and nbowles@mail.rockefeller.edu mcewen@mail.rockefeller.edu mnhill@ucalgary.ca.); Hill MN ( Laboratories of Neuroendocrinology and Departments of Cell Biology and Anatomy and Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada T2N 4N1 nbowles@mail.rockefeller.edu mcewen@mail.rockefeller.edu mnhill@ucalgary.ca.); |
| Abstract |
Glucocorticoids are known to promote the development of metabolic syndrome through the modulation of both feeding pathways and metabolic processes; however, the precise mechanisms of these effects are not well-understood. Recent evidence shows that glucocorticoids possess the ability to increase endocannabinoid signaling, which is known to regulate appetite, energy balance, and metabolic processes through both central and peripheral pathways. The aim of this study was to determine the role of endocannabinoid signaling in glucocorticoid-mediated obesity and metabolic syndrome. Using a mouse model of excess corticosterone exposure, we found that the ability of glucocorticoids to increase adiposity, weight gain, hormonal dysregulation, hepatic steatosis, and dyslipidemia was reduced or reversed in mice lacking the cannabinoid $CB_{1}$ receptor as well as mice treated with the global $CB_{1}$ receptor antagonist AM251. Similarly, a neutral, peripherally restricted $CB_{1}$ receptor antagonist (AM6545) was able to attenuate the metabolic phenotype caused by chronic corticosterone, suggesting a peripheral mechanism for these effects. Biochemical analyses showed that chronic excess glucocorticoid exposure produced a significant increase in hepatic and circulating levels of the endocannabinoid anandamide, whereas no effect was observed in the hypothalamus. To test the role of the liver, specific and exclusive deletion of hepatic $CB_{1}$ receptor resulted in a rescue of the dyslipidemic effects of glucocorticoid exposure, while not affecting the obesity phenotype or the elevations in insulin and leptin. Together, these data indicate that glucocorticoids recruit peripheral endocannabinoid signaling to promote metabolic dysregulation, with hepatic endocannabinoid signaling being especially important for changes in lipid metabolism. |
| ISSN |
00278424 |
| e-ISSN |
10916490 |
| Journal |
Proceedings of the National Academy of Sciences of the United States of America |
| Issue Number |
1 |
| Volume Number |
112 |
| Language |
English |
| Publisher |
National Academy of Sciences |
| Publisher Date |
2015-01-01 |
| Publisher Place |
United States |
| Access Restriction |
Open |
| Subject Keyword |
Endocannabinoids Metabolism Glucocorticoids Adverse Effects Metabolic Syndrome X Chemically Induced Animals Corticosterone Pharmacology Dyslipidemias Administration & Dosage Liver Pathology Mice, Inbred C57BL Obesity Organ Specificity Drug Effects RNA, Messenger Genetics Receptor, Cannabinoid, CB1 Antagonists & Inhibitors Signal Transduction Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Multidisciplinary |
| Content Type |
Text |
| Resource Type |
Article |
| Subject |
Multidisciplinary |
